It was shown in a prospective study that serum FGF21 levels were increased in patients with NAFLD/NASH, and this study was also the first to find that FGF21 mRNA expression was significantly increased in human liver with NAFLD (44). Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.